Experts support continued use of Aranesp in certain kidney patients

10/18/2010 | Bloomberg

An FDA advisory panel voted 15-1 for continued use of Amgen's Aranesp in nondialysis patients with chronic kidney disease. The panel also voted 9-5 against lowering dosing for patients with blood hemoglobin levels less than 9 grams per deciliter. The advisers recommended further studies to determine the ideal dosing and to identify which patients benefit from Aranesp.

View Full Article in:

Bloomberg

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Regional Director, Southeastern Region - State Affairs
America's Health Insurance Plans (AHIP)
Washington, DC
Sr. Principal Electrical Engineer - 14000008LR
Abbott
San Jose, CA
Director, Compliance - Health Plan Privacy & Security
Kaiser Permanente
Oakland, CA
Systems Test - V&V Engineer - 14000008LS
Abbott
San Jose, CA
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC